Crinum jagus: antiproliferative studies of extracts on HepG2 cell line and in silico assessment of phytoconstituents as potential inhibitors of p53–mortalin interaction

Future Journal of Pharmaceutical Sciences

Table 6 Pharmacokinetic properties of phytoconstituents identified in Crinum jagus extracts

Compound	GI	BBB	Pgp	BS	WLOGP	SA
Neophytadiene	Low	No	Yes	0.55	7.17	4.08
Hexadecanoic acid methyl ester	High	Yes	No	0.55	5.64	2.53
n-hexadecanoic acid	High	Yes	No	0.85	5.55	2.31
3′,4′,5,6,7,8-hexamethoxyflavone (Nobiletin)	Low	No	Yes	0.17	0.69	6.10
Eicosane	Low	No	No	0.55	8.05	2.72
4′,5,6,7,8-pentamethoxyflavone (Tangeretin)	High	Yes	No	0.55	3.50	3.74
Stearic acid	High	No	No	0.85	6.33	2.54
Eicosanoic acid	Low	No	No	0.85	7.11	2.77
Docosanoic acid	Low	No	No	0.85	7.89	3.00
Hexadecanoic acid ethyl ester	High	No	No	0.55	6.03	2.80
Galanthamine	High	Yes	Yes	0.55	1.32	4.57
Crinamine	High	Yes	No	0.55	0.65	4.82

GI gastrointestinal absorption, BBB blood–brain barrier, Pgp permeability glycoprotein, BS bioavailability score, SA synthetic accessibility